-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Maiwei Bio-B (02493.HK) announced that the company will announce the phase II clinical study data of targeted Nectin-4 ADC innovative drugs for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received ADC treatment with topoisomerase I inhibitors at the 2026 European Society of Medical Oncology (ESMO) conference to be held in Madrid, Spain from October 23 to October 27, 2026:

Zhitongcaijing·10/19/2026 11:09:22
Listen to the news
Zhitong Financial App News, Maiwei Bio-B (02493.HK) announced that the company will announce the phase II clinical study data of targeted Nectin-4 ADC innovative drugs for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received ADC treatment with topoisomerase I inhibitors at the 2026 European Society of Medical Oncology (ESMO) conference to be held in Madrid, Spain from October 23 to October 27, 2026: